Skip to content
Bored Studies
RecruitingPhase 1/Phase 2

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Eledon Pharmaceuticals · NCT05027906

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–100 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1, Phase 2
Target enrollment
48
US sites recruiting
1
Study start
February 18, 2022
Record last updated
June 29, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.

Being studied: AT-1501

Conditions: Prevention of Rejection in Kidney Transplant

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male or female ≥ 18 years of age
  • Recipient of their first kidney transplant from a living or deceased donor
  • Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug

Exclusion Criteria

  • Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen
  • Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies, with the exception of 5 mg prednisone or equivalent daily;
  • Previous treatment with AT 1501 or any other anti CD40LG therapy
  • The patient has previously received a bone marrow transplant or any other solid organ transplant, including a kidney, or will be undergoing a multi organ or dual kidney transplant
  • Will receive a kidney with an anticipated cold ischemia time of > 30 hours;
  • Will receive a kidney from a donor that meets any of the following criteria:
  • Donation after Cardiac Death (DCD) criteria; or
  • Extended Criteria Donor (ECD) criteria, defined as:
  • Is blood group (ABO) incompatible; or
  • Age ≥ 60 years; or Age 50-59 years with any 2 of the following criteria:
  • Death due to cerebrovascular accident
  • History of hypertension
  • Terminal creatinine ≥ 133 μmol/L (1.5 mg/dL)
  • Human leukocyte antigen identical (two haplotype match or zero HLA mismatch) donor
  • Medical conditions that require chronic use of systemic steroids at a dose higher than 5 mg prednisone or equivalent per day
  • History of a TE event, known hypercoagulable state, or condition requiring long term anticoagulation:
  • Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening

Recruiting US locations

  • University of Cincinnati

    Cincinnati, OH 45267

    Site contact: Research Staff

Study contacts (from the official record)

  • Eledon Pharmaceuticals · 949-238-8090 · clinicaltrials@eledon.com
All phase 1 studies in Ohio →
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients… (NCT05027906) | Bored Studies